How can 2 school meal program studies be combined?
Combining the School Nutrition and Meal Cost Study and School Food Purchase Study
Challenge
The School Nutrition and Meal Cost Study II (SNMCS-II) and the School Food Purchase Study IV (SFPS-IV) are 2 studies funded by the Food and Nutrition Service (FNS) at the U.S. Department of Agriculture (USDA). Both studies are intended to assess the operations and performance of the National School Lunch Program (NSLP) and the School Breakfast Program (SBP).
Because both studies explore school food purchases and procurement practices, FNS seeks to combine the existing study plans for SNMCS-II and SFPS-IV in an integrated way, such that the data for both studies are collected simultaneously.
Solution
Westat conducted a thorough review of each study’s design to identify similarities and differences in sample design, research questions, instruments, recruiting and data collection procedures, and data processing and analysis plans.
We developed options for the combined study plan design and described key considerations for FNS, including
- Implications for burden and response rates
- Validity and precisions of estimates
- Comparability to prior studies
- Potential for new analyses
Results
After FNS selected the preferred design option for the combined study, Westat developed an integrated and updated study plan that combines the studies such that data for both studies are collected during the same school year.
The design aims to keep the burden on individual School Food Authorities (SFAs) within acceptable limits and assure high levels of cooperation and data quality.
-
Expert Interview
Safeguarding Data Privacy: Innovations at WestatOctober 2025
Protecting the privacy of people who respond to surveys and censuses is a critical responsibility in federal data collection. During the 2010 Decennial Census, the…
-
Expert Interview
Novel Strategies Transform Clinical Trials Into Future OpportunitiesOctober 2025
For the rigorous evaluation of novel medicines, clinical trials are essential to ensure safety and efficacy. However, clinical trials are experiencing turbulent times due to…
-
Expert Interview
Real-World Insights: Nirsevimab’s Protection Against RSV in InfantsSeptember 2025
Each year in the U.S., respiratory syncytial virus, commonly known as RSV, leads to approximately 58,000 to 80,000 hospitalizations among children under age 5. The…